PAR5 ADALIMUMAB, ETANERCEPT OR INFLIXIMAB- WHAT IS THE MOST COST-EFFECTIVE ANTI-TNF-á THERAPY IN RA IN A REAL-WORLD SETTING?
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64920-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)64920-0/fulltext
Title :
PAR5 ADALIMUMAB, ETANERCEPT OR INFLIXIMAB- WHAT IS THE MOST COST-EFFECTIVE ANTI-TNF-á THERAPY IN RA IN A REAL-WORLD SETTING?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64920-0&doi=10.1016/S1098-3015(10)64920-0
First page :
Section Title :
Open access? :
No
Section Order :
79